Experts discuss the CLEOPATRA trial outcomes, taxane nuances, and evolving strategies in first-line treatment. They review practical considerations and ongoing trials and dive into the dynamic landscape of managing metastatic HER2+ breast cancer, anticipating transformative developments.
Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.
Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.
Clinicians explore disparities and similarities in desmoid tumor treatment approaches between academic and community settings, considering access to clinical trials, shared decision-making, and patient education for better outcomes.
Delve into the NCCN guidelines and contemporary treatments for desmoid tumors and explore the multidisciplinary approach, limitations, and current standard care options for enhanced patient outcomes.